Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where is the short covering? The shorts have an amazing opportunity to cover at 1.00 and they saw the pps hit .80. WTF are they waiting for? Is .50 all that likely? With Gonzalataco running the show, maybe they are right. They should probably wait for .15 and the coming secondary offering once the stock hits .15.
Brent Larson's sells are certainly not a mystery any longer.
Does this sound familiar?
I posted this on December 22nd here (post #8261). Looks like I'm right 3 out of 4, so far.
The next four disappointments to come from Navidea will be:
1. A completed 4694 deal that insults the NAVB shareholder and puts lets than $1 million in cash in Navidea's cash starved hands. The sad reality is that the company spent at least $20 million on 4694, so why they hold out now for an extra $100K or $200K is beyond me, unless of course, it is to give the appearance that the company is even worse shape than it is (and help the shorts grip on the stock). Watch and see.
2. Q4 sales will stink out loud. The figure will be under $4 million. The company is notorious for overestimating and overstating sales and revenue expectations. The only sales that are definite are Brent Larson's SALES of every single NAVB share he has before 2016. Watch and see.
3. Manocept will not be spun off until Q1 2017 according to the company and their recent 10Q. This really means it could be 2018, 2019, or NEVER! And the corresponding spinoff shares awarded to NAVB shareholders will be a pittance. Wait and see. Brent Larson is dumping all the NAVB he can. Clearly, he seems to have no interest in the spinoff shares to be doled out at a later date. Watch and see.
4. Lymphoseek sales in Europe will be delayed as long as possible to ram it to the shareholder. Q1 2017? Nah, the company will likely wait much longer than that. The nonsense about premium pricing is just more delay and rhetoric to justify VERY LOUSY SALES IN ADVANCE FOR 2016. Watch and see.
Can I be labeled as an Oldtimer when I buy my first block of NAVB at .08? It sure looks like that's where this is headed.
This article sums up the current state of NAVB all too well:
http://newswatchinternational.com/news/company-shares-of-navidea-biopharmaceuticals-inc-nysemktnavb-drops-by-5-67.html
Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) has lost 5.67% during the past week and dropped 10.74% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 4.89%. Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) has underperformed the index by 8.65% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Navidea Biopharmaceuticals, Inc has dropped 41.41% during the last 3-month period . Year-to-Date the stock performance stands at -29.63%.
Shares of Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) ended Thursday session in red amid volatile trading. The shares closed down 0.01 points or 0.75% at $1.33 with 458,401 shares getting traded. Post opening the session at $1.34, the shares hit an intraday low of $1.32 and an intraday high of $1.37 and the price vacillated in this range throughout the day. The company has a market cap of $207 million and the number of outstanding shares have been calculated to be 155,699,670 shares. The 52-week high of Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) is $2.495 and the 52-week low is $1.22.
Currently the company Insiders own 2.1% of Navidea Biopharmaceuticals, Inc. shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -10.11% . Institutional Investors own 35.63% of Navidea Biopharmaceuticals, Inc. shares. During last six month period, the net percent change held by insiders has seen a change of -21.95%. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The officer (EVP, CFO, Treas & Secy), of Navidea Biopharmaceuticals, Inc., Larson Brent L had unloaded 12,500 shares at $1.5 per share in a transaction on December 1, 2015. The total value of transaction was $18,750. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Oldtimers are growing impatient and understandably so.
From their board today:
"- NAV4694: F - still waiting for NAV4694 to be divested or monetized after almost 20 months. If we do not get ~$9MM+ in upfront payments, it would have been better to shutdown the program in May of 2014 (when it was decided to divest it)."
My reply:
Yup. What a terrible waste of company money and precious investor sentiment. This imbalance of money spent on 4694 vs. what the company will ever recover in the deal has alone damaged the company reputation just as bad as Crede.
$750K no matter what
is enough to make RG sip Coffee like he is a millionaire already. He needn't care about Navidea or the shareprice - simply milking a weekly paycheck for as long as he can and waiting for the inevitable severance like Pykett got.
The next four disappointments to come from Navidea will be:
1. A completed 4694 deal that insults the NAVB shareholder and puts lets than $1 million in cash in Navidea's cash starved hands. The sad reality is that the company spent at least $20 million on 4694, so why they hold out now for an extra $100K or $200K is beyond me, unless of course, it is to give the appearance that the company is even worse shape than it is (and help the shorts grip on the stock). Watch and see.
2. Q4 sales will stink out loud. The figure will be under $4 million. The company is notorious for overestimating and overstating sales and revenue expectations. The only sales that are definite are Brent Larson's SALES of every single NAVB share he has before 2016. Watch and see.
3. Manocept will not be spun off until Q1 2017 according to the company and their recent 10Q. This really means it could be 2018, 2019, or NEVER! And the corresponding spinoff shares awarded to NAVB shareholders will be a pittance. Wait and see. Brent Larson is dumping all the NAVB he can. Clearly, he seems to have no interest in the spinoff shares to be doled out at a later date. Watch and see.
4. Lymphoseek sales in Europe will be delayed as long as possible to ram it to the shareholder. Q1 2017? Nah, the company will likely wait much longer than that. The nonsense about premium pricing is just more delay and rhetoric to justify VERY LOUSY SALES IN ADVANCE FOR 2016. Watch and see.
Serious question: Will there ever be another insider buy? The lack of insider buys coupled with the lack of any updates at all from the company on MT tells me that they already know MT is garbage and headed no where EVER!
This constant abuse and neglect of shareholders by Navidea is becoming quite tiresome. Sure, Martin S. was arrested today. So what! It does nothing to fix all that is wrong with NAVB.
The lower NAVB goes, the less Brent Larson gets for his sells. This is the only good thing I see as I follow the daily trading pattern of garbage NAVB.
It is looking like NAVB will not see 2.00 in 2016 - and if it approaches 2.00, I can't imagine the enormous resistance there will be at 2.00 this time.
The TASE listing was a gift to the Oldtimers to let them out without informing the rest of us that this garbage stock was dead. An investigation is warranted. Congratulations to UBD on the Oldtimers board for being out of NAVB altogether!
Short interest down again, but so is the share price also down again.
There were 100,000 shares on the ASK today at 1.45. A short could have covered and locked in a fortune. Instead our volume was 247,000 without any major interest in the ASK at 1.45.
The appearance here is that 2016 is going to be dreadful and the company doesn't give a damn. Is it time to give Gonzalez $750K and send him on his way? After all, the share price is now below the pps when he took over. Dark days ahead. I try not to imagine what bad news would do to the pps when silence only drives the pps down. Now I understand why there are no insider buys though. There is nothing of substance to report because Manocept is a complete farce and the company already knows it.
How did the shorts know four years ago that the company would never get anything right?
Short interest down again, but so is the share price also down again.
There were 100,000 shares on the ASK today at 1.45. A short could have covered and locked in a fortune. Instead our volume was 247,000 without any major interest in the ASK at 1.45.
The appearance here is that 2016 is going to be dreadful and the company doesn't give a damn. Is it time to give Gonzalez $750K and send him on his way? After all, the share price is now below the pps when he took over. Dark days ahead. I try not to imagine what bad news would do to the pps when silence only drives the pps down. Now I understand why there are no insider buys though. There is nothing of substance to report because Manocept is a complete farce and the company already knows it.
How did the shorts know four years ago that the company would never get anything right?
I'll say this for Navidea, they aren't falsifying good news just to boost the share price. Indeed, they aren't saying a thing and in turn, there are no buyers.
For all the money the company has put into 4694, it seems EXCEPTIONALLY UNLIKELY that ANY deal will be worth even 10% of the total money invested in the R and D expenses sunk into it over the past 3 years. And when the lousy deal terms are finally announced, will the share price hold 1.00? Seems as if the shorts sure picked a winner here. Maybe Navidea will get $200K up front and a guaranteed 5% of all future sales of 4694 related product. While this may sound unduly sarcastic, given the history of Crede deals and daily free spending with our Dublin based dunces, the deal terms could be even worse (assuming they ever materialize at all).
I envy those that have never heard of Navidea. To all of them, I offer congratulations!
Short interest down 1.3% and pps way down. Longs are letting some shorts off easy. Maybe Brent Larson's next batch of sold shares will benefit the shorts. He and Gonzalez can laugh it up over drinks. 381,000 shares is nothing. This game is going to make 2016 more miserable than we can imagine. Thanks Rick!
The molestation of shareholders continues. Lock up Gonzalez and Larson with Jared Fogel! Does NAVB get down to 1.34 today? Does Gonzalez give a damn? Hell, I think Navidea should wait until 2089 to launch the MT spinoff. By stating in the 10Q that the spinoff won't happen until Q1 2017 AT THE EARLIEST, they destroyed what little credibility they had left.
The lower the pps goes, the less Brent Larson gets on 12/1 when he sells another 12,500 shares. Hell, by then we could be at .64 and sliding lower.
2016 will be terrible for NAVB stock and the joke of a company known as Navidea. The company has wasted unimaginable millions on 5001 and 4694 and shareholders have suffered as a result. Perhaps the most telling reality here is that NO INSIDERS ARE BUYING, EVEN AT 1.50!
Thanks. I just saw your message today. Oops.
Come on PUMPERS! The lower NAVB gets, the better you can say it is!
At 1.53 tomorrow, you can call it a "great buying opportunity."
At 1.39 next week, you can call it a "steal."
At 1.16 in early December, you can call it "the stock of the century!"
Do you know what Larson and Gonzalez are calling YOU? I'll tell ya!
"Dumb for owning 2,000 shares and retarded for owning 4,000!"
Navidea has molested the unholy F*** out of shareholders.
It is time for shareholder lawsuits, new management changes, updates on all fronts like MT and 4694, and no more nonsense forward looking statements that are known by Gonzalez and Larson to be false in advance.
Sorry, RG! You are in charge and the TASE listing was nothing more than a parlor trick. For all we know, the company itself sold into the run to 2.50. May their brains be smashed apart!
One GREAT thing about this ever sliding lower pps is that Bernt Larson will get less and less now for every share that he sells AND RIGHTFULLY SO! How about .50 per share in 2 weeks...seems to be where NAVB is headed.
When do we hear about the next Crede style deal?
When will insiders buy? I'll ask that again: WHEN WILL INSIDERS BUY?
There is always the appearance that huge downslides in pps are deliberate with Navidea. There was NO REASON to list on the TASE when not a single MT development has been announced since the listing!
The nonsense needs to stop and heads need to come off!
The fact that we are not seeing any insider buying (and all we do see is prescheduled Brent Larson selling) tells me many things:
1) Manocept is complete nonsense. When Navidea tries to list the MT subsidiary on the TASE, I bet it goes down daily. The way NAVB has performed since being on the TASE certainly has not impressed Israeli investors.
2) 4694 will be thrown away for next to nothing.
3) Navidea is not worth buying out - if they were, it would have happened long ago at this sub $2 share price.
4) The 12 member sales team is just another expense that the company can't really afford. And very sadly, the sales teams "best" effort only added $1 million in revenue for Navidea. Their 12 salaries are likely much more than $1 million. Even when the company APPEARS to be acting wise, they're really just wasting more money. Lovely!
5) The NAVB shareholder will be treated very poorly if and when a real MT spinoff is ever announced. The number of shares in MT that will be awarded to NAVB shareholders will be minimal. Perhaps 20% of the initial MT float will be distributed AND AS RESTRICTED STOCK (and then only sellable in 3 years).
If all of my points are wrong, then Gonzalez himself would be buying NAVB shares, especially at 1.84, instead of buying more black beans and tacos. Too many investors have already bought into his nonsense thus far and are now very unhappy. Those of us that have been here for more than a year or two are just accustomed to Navidea fraud and mismanagement. It took 15 million TASE shares to move NAVB to 2.40 for a day. It will take hundreds of millions of shares to ever get it back there. Navidea executives seem to enjoy laughing at and mocking their own shareholders daily. May their party end soon!
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Where are the insider buys?
Sure DDbuyer. NAVB is FINE! The pps has dropped from a high of 2.50 to bottom at 1.73 two days ago and the stock is mired in the 1.70s now. If 5 Vice-Presidents were eliminated AND THE PR SAID THAT OTHER NAVIDEA EMPLOYEES WERE ABSORBING THEIR RESPONSIBILITIES, THE PPS WOULD SOAR. Navidea wants shareholders to suffer.
How about if Navidea gets listed on stock exchanges in Africa, Antarctica, Greenland, and Mexico? This should be great for a 10 second pop before the pps slides even lower.
And no one else has said this yet, but I am not convinced that Q4 will be solid at all - the "dirty dozen" only added $1 million in revenue for Navidea in this past quarter. I'll bet their combined salaries are more than that. Way to go Gonzalez!
The company keeps saying that they're on track for every goal blah blah blah. If so, then I have a question: WHERE ARE THE INSIDER BUYS AT THIS PPS OR INSIDER BUYS IN GENERAL?!
What was the point of the TASE listing? Sales are still insignificant and the pps here and abroad is back under 2.00. Was it done so Larson could make a few extra dollars when he sells? Gotta wonder.
It's refreshing to finally hear DDbuyer talk about the company eliminating some of the Vice-Presidents..Brent Larson would make a great cut in the first round of eliminations.
Short interest is down 2.105 million shares...are these shares being reshorted?
What WOULD help the share price:
Michael Myers visits Dublin and takes care of business. No more RG, BL, or any of the other chuckleheads survive. :)
Jason Vorhees visits the shorts in their offices and smashes their computers over their heads.
Current management AND the shorts eliminated in the same day?!
THAT would move the pps!
THERE IS NO WAY in this world that the Navidea shareholder will own 95% of the spinoffs. At least 50% of the MT shares will be sold on the open market to new investors at the IPO to raise money for MT. The last thing Gonzalez and Larson want is to reward loyal shareholders with anything.
I laugh as you use the plural form of spinoffs. Yes, the company has hinted at the potential of multiple spinoffs, but all I see is a stock that is down more than 25% off its high BECAUSE ALL THE COMPANY DOES IS TALK. Nothing formal regarding the enhancement of shareholder value through MT is ever established. Everything is a tease.
Market surges today...Navidea falls back further.
Yeah, this feels real familiar AND TIRED!
No wonder Brent Larson is selling.
Good call on 2.07 or lower casperboo. One wonders why the company bothered with TASE if they have absolutely no news, progress, or developments to keep the price above 2.00.
1.85 tomorrow? Just how bad will earnings be? Was the rise in price orchestrated just for the shorts benefit?
Been abused by Navidea too long to think positive. Maybe the pps can get below 1.00 before 11/1 so good ol Brent Larson doesn't get crap for his monthly dump of 12,500 shares.
Does this garbage stock see 2.07 today? It sure seems likely to me.
The buyers are gone and the volume has fallen off. Tomorrow this garbage stock sees 2.14 or lower. The shorts will be knocking this back to 1.80 or lower within 3 weeks. To make matters worse, I bet the company has no substantial PR until earnings around 11/4. If earnings disappoints, don't be surprised gentleman. Alf33 made a post on the Oldtimers Board that no one can argue with and he is right. This nonsense about needing another full year to get Lymphoseek selling in Europe is beyond ridiculous!
More delay, more delay...same old story.
How many free shares for Larson this week?
Nice turnaround here gentlemen. GLTA.
Short interest is up 4.4% with 1,361,957 shares shorted in the past quarter making the total short interest 32,430,059.
Gee Rick Gonzalataco, that 4694 partnership could really help continue the partial fix of the NAVB pps that you started with the TASE addition. Please Ricky, tell us that there is more to your talent than a one month pps rise based solely on a new exchange. I'd like real substance as would everyone else!
DDbuyer doesn't seem too bright today. That million share block seems more like shorting and the shorting seems to be continuing as we slide under 2.20. Lovely.
Is it voodoo or black magic? What happened to all the buyers? Are they hiding in a magician's hat? This type of bleed down is exactly what I was afraid of...Thanks Gonzalez. Why didn't you wait for TASE when you had a steady stream of good MT/partnership news to share? Taco on the brain, I guess...
The TASE addition has been a long overdue boost for our underperforming NAVB.
But how long can this pps last in the 2.20s-2.50 without some real MT news or a significant increase in revenues when the Q3 numbers come out? How about that 4694 partnership? The company will need a year in Europe to realize premium pricing? Approval in the EU came more than a year ago. Delay, delay, delay needs to be replaced with SUCCESS, SUCCESS, SUCCESS or the pps will slide under 2.00 again. Not bashing, just very familiar with how classic Larson/Navidea inaction eventually gets recognized by the market (and impatient NAVB investors such as myself).
Q3 Revenue for Navidea of $3,000,000 would be a 50% increase over the $1,980,000 million they had for Q2 - BUT I SERIOUSLY DOUBT THAT Q3 will be anything above $2.5 million. If it is, I will be wrong. But what matters more than my rightness or wrongness is what revenue will move the pps up from here. $3 million has a chance to matter, but does it have a chance to happen for Q3?
I know this much! $3.5 million OR MORE BETTER HAPPEN FOR Q4!
VERY STRONG close. I am again pleasantly surprised. As the earnings announcement nears, we should see real movement up from our high of 2.50 if Q3 will be good.
It will be interesting to see if a 20% increase in sales (meaning a Q3 of $2.4 million for Navidea) will move the price up or keep it as is.
GLTA.
2.15 or lower today, now that TASE has been stocked with all necessary shares?
It sure would be nice if Navidea would release news to support or propel the pps higher. The NAVB share holder has certainly been abused enough.
VOLATILITY CITY. EOM.
The third quarter is over today. In about 4 weeks we'll know if this stock has any chance of sustaining this amazing run. Let's hope that the dirty dozen did more than eat doughnuts this summer. Q3 numbers will be pivotal.
NAVB very strong today. I am surprised. Whatever nonsense happened at the open Monday to put the pps at 2.03 and 2.06 sure didn't work.
Unfortunately, Brent Larson will wrongfully benefit from this strength tomorrow.